{name}
{subtitle}
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
city
~52 mi. (Catanzaro, Italy, +141 more cities)
facility
GSK Investigational Site
drug type
chemotherapy, +1 more type